Complex biomarker tests for molecularly targeted therapies lack evidentiary standards

[News]

Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions.

More... (http://www.news-medical.net/news/20160307/Complex-biomarker-tests-for-molecularly-targeted-therapies-lack-evidentiary-standards.aspx)